Your session is about to expire
← Back to Search
Other
AV-101 for Drug Interaction
Phase 1
Waitlist Available
Research Sponsored by VistaGen Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours
Awards & highlights
Study Summary
This trial is testing a new drug, AV-101, to see how it is affected by probenecid and how it affects the body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Plasma and CSF concentrations of 4-chloro-kynurenine (AV-101) in ng/ml
Plasma and CSF concentrations of 7-chloro-kynurenic acid (7-Cl-KYNA) in ng/ml
Side effects data
From 2015 Phase 3 trial • 242 Patients • NCT0132072213%
Abdominal discomfort
8%
Fatigue
8%
Decreased appetite
6%
Altered taste
6%
Joint pain
6%
Elevated liver enzymes
6%
Elevated creatinine
6%
Nausea
4%
Transient shortness of breath
4%
Dizziness
4%
Headache
4%
Tingling in extremities
2%
Transient nose bleed
2%
Sleepiness
2%
Sensitivity to touch
2%
Diarrhea
2%
Heartburn
2%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Allopurinol
Vitamin D
Placebo- Vitamin D
Probenecid
Placebo- Uric Acid
Trial Design
2Treatment groups
Experimental Treatment
Group I: AV-101 + ProbenecidExperimental Treatment2 Interventions
AV-101 360 mg oral capsules + 1000 mg Probenecid
Group II: AV-101Experimental Treatment1 Intervention
AV-101 360 mg oral capsules single dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Probenecid
FDA approved
AV-101
Not yet FDA approved
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
ParexelIndustry Sponsor
304 Previous Clinical Trials
101,128 Total Patients Enrolled
VistaGen Therapeutics, Inc.Lead Sponsor
9 Previous Clinical Trials
1,561 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger